Bioanalysis Zone

Novel ADME biomarkers and HRMS move new medicines to patients faster

0

In this interview with Ragu Ramanathan (Pfizer; NY, USA), Ragu describes his current research focuses in measuring and quantitating drugs and metabolites in animal and human samples. Ragu discusses the key challenges associated with studying drug/drug interactions (DDI), the benefits of current technologies available for studying DDI and what to expect from the upcoming Special Focus Issue from Bioanalysis on ‘Novel LC–MS assays impacting CYP and transporter DDI evaluation’.

Related resources:

 

If you liked this interview, you might also like:

Share:

Leave A Comment